Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
Authors
Keywords
-
Journal
RMD Open
Volume 9, Issue 1, Pages e002859
Publisher
BMJ
Online
2023-02-16
DOI
10.1136/rmdopen-2022-002859
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial
- (2022) Elizabeth R Volkmann et al. RHEUMATOLOGY
- Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
- (2021) Kristin B Highland et al. Lancet Respiratory Medicine
- Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease
- (2021) David Roofeh et al. Arthritis & Rheumatology
- OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)
- (2021) R. Spiera et al. ANNALS OF THE RHEUMATIC DISEASES
- Nintedanib in patients with systemic sclerosis‐associated interstitial lung disease: subgroup analyses by autoantibody status and skin score
- (2021) Masataka Kuwana et al. Arthritis & Rheumatology
- Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
- (2020) Anna-Maria Hoffmann-Vold et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Dinesh Khanna et al. Lancet Respiratory Medicine
- Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
- (2019) Wanlong Wu et al. ANNALS OF THE RHEUMATIC DISEASES
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
- (2019) Oliver Distler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort
- (2019) Anna-Maria Hoffmann-Vold et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases
- (2019) Lutz Wollin et al. EUROPEAN RESPIRATORY JOURNAL
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis – Results of a Phase 2 Investigator‐Initiated, Multicenter, Double‐Blind Randomized Placebo‐Controlled Trial
- (2019) Dinesh Khanna et al. Arthritis & Rheumatology
- Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database
- (2019) Camelia Frantz et al. AUTOIMMUNITY REVIEWS
- Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts
- (2018) Elizabeth R Volkmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort
- (2010) Shervin Assassi et al. ARTHRITIS RESEARCH & THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now